Advaxis, Inc. (NASDAQ:ADXS) has reached an agreement, with its parent company, Synthetic Genomics Inc, for a five year exclusive supply for synthetic DNA. ADXS expects to use this in personalized Listeria monocytogenes (Lm) based immunotherapy (MINE). The goal of the therapy is to develop neo-epitope immunotherapy, based on the patient’s own unique neo-epitopes, found in the tumor.

SGI would use the unique neo-epitopes, provided by Advaxis, in DNA plasmids, which would then be added to the specific immunotherapy constructs, by Advaxis. The resulting therapy would target the patient specific neo-epitope sequences, in the tumor. Daniel O’Connor, the CEO of ADXS, stated that SGI is unparalleled in its commitment to genomic services and has the ability to support DNA synthesis of the company’s therapies. He also revealed that the company plans to file for an Investigational New Drug application, in the later part of 2016.

Apart from developing new patient specific immunotherapy, Advaxis has also begun the dose administration of AXAL, as part of the phase-2 clinical trials, targeted at label expansion of the drug. The company is testing the drug to target patients with PRmCC. As per the details of the study, it is expected to update the company on the safety, immunological effect and efficacy of the drug in patients. The dose would be administered in repeat cycles, to 25 women, with cervical cancer and whose disease recurred after the initial treatments. The CEO of ADXS believes that the company can fill an unmet medical need of women with recursive cervical cancer.

Furthermore, Advaxis has also revealed that the company COO, Gregory Mayes, would be presenting at the 27th Annual ROTH Capital Partners Conference, in California. He is expected to update the audience on the current plans of the company, for 2016. The conference would be held on March 15, with the presentation starting at 11am.

Advaxis, Inc. (NASDAQ:ADXS) completed the March 9 session, with a gain of 0.82%, in its share value, to reach a close at $8.63.